A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility

Nature Communications

Volumn 5, Issue , 2014, Pages

  Christensen, Claus ^a   Bartkova, Jirina ^a   Mistrík, Martin ^a,b   Hall, Arnaldur ^a   Lange, Marina Krarup ^a   Ralfkiær, Ulrik ^a,c   Bartek, Jiri ^a,b   Guldberg, Per ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; ASPARTIC ACID; BH3 PROTEIN; CYTOPLASM PROTEIN; GLYCINE; PROTEIN BCL XL; PROTEIN P53; SUPEROXIDE; BCL2L1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN BCL X;

ACID; CYTOPLASM; INHIBITION; MITOCHONDRIAL DNA; MUTATION; PROTEIN; STEADY-STATE EQUILIBRIUM;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CDKN2A GENE; CELL PROTECTION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; GERMLINE MUTATION; HOMEOSTASIS; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MOUSE; NEWBORN; NONHUMAN; ONCOGENE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REDOX STRESS; CELL CULTURE; CELL RESPIRATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM;

AMINO ACID MOTIFS; BCL-X PROTEIN; CELL RESPIRATION; CELLS, CULTURED; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MELANOCYTES; MELANOMA; MITOCHONDRIAL DISEASES; SUPEROXIDES; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 84923364286     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6348     Document Type: Article

References (64)

1. Sherr, C. J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6, 663-673 (2006).
2. Zindy, F. et al. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc. Natl Acad. Sci. USA 100, 15930-15935 (2003).
3. Churchman, M. L., Roig, I., Jasin, M., Keeney, S. & Sherr, C. J. Expression of arf tumor suppressor in spermatogonia facilitates meiotic progression in male germ cells. PLoS Genet. 7, e1002157 (2011).
4. Sharpless, N. E. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res. 576, 22-38 (2005).
5. Weber, J. D. et al. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 14, 2358-2365 (2000).
6. Paliwal, S. et al. Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol. 26, 2360-2372 (2006).
7. Kelly-Spratt, K. S., Gurley, K. E., Yasui, Y. & Kemp, C. J. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol. 2, E242 (2004).
8. Quelle, D. E., Zindy, F., Ashmun, R. A. & Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993-1000 (1995).
9. Bertwistle, D., Sugimoto, M. & Sherr, C. J. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol. Cell Biol. 24, 985-996 (2004).
10. Reef, S. et al. A short mitochondrial form of p19ARF induces autophagy and caspase-independent cell death. Mol. Cell 22, 463-475 (2006).
11. Abida, W. M. & Gu, W. p53-dependent and p53-independent activation of autophagy by ARF. Cancer Res. 68, 352-357 (2008).
12. Velimezi, G. et al. Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. Nat. Cell Biol. 15, 967-977 (2013).
13. Hussussian, C. J. et al. Germline p16 mutations in familial melanoma. Nat. Genet. 8, 15-21 (1994).
14. Goldstein, A. M. et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 66, 9818-9828 (2006).
15. Meyle, K. D. & Guldberg, P. Genetic risk factors for melanoma. Hum. Genet. 126, 499-510 (2009).
16. Randerson-Moor, J. A. et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum. Mol. Genet. 10, 55-62 (2001).
17. Rizos, H. et al. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 20, 5543-5547 (2001).
18. Hewitt, C. et al. Germline mutation of ARF in a melanoma kindred. Hum. Mol. Genet. 11, 1273-1279 (2002).
19. Cust, A. E. et al. Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK. J. Med. Genet. 48, 266-272 (2011).
20. Bishop, D. T. et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J. Natl Cancer Inst. 94, 894-903 (2002).
21. Berwick, M. et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol. Biomarkers Prev. 15, 1520-1525 (2006).
22. Zindy, F. et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12, 2424-2433 (1998).
23. Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724 (2005).
24. Haferkamp, S. et al. Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors. J. Invest. Dermatol. 129, 1983-1991 (2009).
25. den Besten, W., Kuo, M. L., Williams, R. T. & Sherr, C. J. Myeloid leukemia- associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 4, 1593-1598 (2005).
26. Cheng, K. et al. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene 26, 7391-7400 (2007).
27. Pimkina, J., Humbey, O., Zilfou, J. T., Jarnik, M. & Murphy, M. E. ARF induces autophagy by virtue of interaction with Bcl-xl. J. Biol. Chem. 284, 2803-2810 (2009).
28. Sahin, E. et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470, 359-365 (2011).
29. Wallace, D. C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 39, 359-407 (2005).
30. Balaban, R. S., Nemoto, S. & Finkel, T. Mitochondria, oxidants, and aging. Cell 120, 483-495 (2005).
31. Hutter, E. et al. Senescence-associated changes in respiration and oxidative phosphorylation in primary human fibroblasts. Biochem. J. 380, 919-928 (2004).
32. Hall, A. et al. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget 4, 584-599 (2013).
33. Haq, R. et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 23, 302-315 (2013).
34. Sviderskaya, E. V. et al. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J. Natl Cancer Inst. 95, 723-732 (2003).
35. Stockl, P., Hutter, E., Zwerschke, W. & Jansen-Durr, P. Sustained inhibition of oxidative phosphorylation impairs cell proliferation and induces premature senescence in human fibroblasts. Exp. Gerontol. 41, 674-682 (2006).
36. Jones, R. G. et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283-293 (2005).
37. Jenkins, N. C. et al. The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene 30, 265-274 (2011).
38. Itahana, K. & Zhang, Y. Mitochondrial p32 is a critical mediator of ARF-induced apoptosis. Cancer Cell 13, 542-553 (2008).
39. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005).
40. Vander Heiden, M. G. et al. Bcl-xL promotes the open configuration of the voltage-dependent anion channel and metabolite passage through the outer mitochondrial membrane. J. Biol. Chem. 276, 19414-19419 (2001).
41. Alavian, K. N. et al. Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase. Nat. Cell Biol. 13, 1224-1233 (2011).
42. Chen, Y. B. et al. Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potential. J. Cell Biol. 195, 263-276 (2011).
43. Narendra, D., Tanaka, A., Suen, D. F. & Youle, R. J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795-803 (2008).
44. Weber, J. D. et al. Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol. Cell Biol. 20, 2517-2528 (2000).
45. Rizos, H., Darmanian, A. P., Mann, G. J. & Kefford, R. F. Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Oncogene 19, 2978-2985 (2000).
46. Lohrum, M. A., Ashcroft, M., Kubbutat, M. H. & Vousden, K. H. Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. Curr. Biol. 10, 539-542 (2000).
47. Itahana, K. et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 12, 1151-1164 (2003).
48. Irvine, M. et al. Amino terminal hydrophobic import signals target the p14(ARF) tumor suppressor to the mitochondria. Cell Cycle 9, 829-839 (2010).
49. Zhang, Y. & Xiong, Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 3, 579-591 (1999).
50. Feng, W., Huang, S., Wu, H. & Zhang, M. Molecular basis of Bcl-xL's target recognition versatility revealed by the structure of Bcl-xL in complex with the BH3 domain of Beclin-1. J. Mol. Biol. 372, 223-235 (2007).
51. Campisi, J. Cancer and ageing: rival demons? Nat. Rev. Cancer 3, 339-349 (2003).
52. Demenais, F. et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J. Natl Cancer Inst. 102, 1568-1583 (2010).
53. Budina-Kolomets, A., Hontz, R. D., Pimkina, J. & Murphy, M. E. A conserved domain in exon 2 coding for the human and murine ARF tumor suppressor protein is required for autophagy induction. Autophagy 9, 1553-1565 (2013).
54. Reef, S., Shifman, O., Oren, M. & Kimchi, A. The autophagic inducer smARF interacts with and is stabilized by the mitochondrial p32 protein. Oncogene 26, 6677-6683 (2007).
55. Itahana, K., Clegg, H. V. & Zhang, Y. ARF in the mitochondria: the last frontier? Cell Cycle 7, 3641-3646 (2008).
56. Rubinstein, A. D., Eisenstein, M., Ber, Y., Bialik, S. & Kimchi, A. The autophagy protein Atg12 associates with antiapoptotic Bcl-2 family members to promote mitochondrial apoptosis. Mol. Cell 44, 698-709 (2011).
57. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
58. Pleasance, E. D. et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196 (2010).
59. Kawanishi, S., Hiraku, Y. & Oikawa, S. Mechanism of guanine-specific DNA damage by oxidative stress and its role in carcinogenesis and aging. Mutat. Res. 488, 65-76 (2001).
60. Kirkin, A. F. et al. Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol. Immunother. 41, 71-81 (1995).
61. Christensen, C. & Guldberg, P. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knock-down of mutated (V600E) B-RAF. Oncogene 24, 6292-6302 (2005).
62. Dahl, C. et al. Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14ARF and RARbeta signaling. Mol. Cancer Res. 11, 1166-1178 (2013).
63. Sage, J. M., Gildemeister, O. S. & Knight, K. L. Discovery of a novel function for human Rad51: maintenance of the mitochondrial genome. J. Biol. Chem. 285, 18984-18990 (2010).
64. Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).